Arcus Biosciences (RCUS) EBITDA (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly EBITDA came in at -$134.0 million in Q1 2026, down 9.84% year-on-year from -$148.6 million in Q1 2025, and down 17.54% quarter-over-quarter from -$114.0 million in Q4 2025.
Arcus Biosciences (RCUS) EBITDA (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBITDA history runs 10 years deep, the most recent figure standing at -$134.0 million for Q1 2026.
- On a quarterly basis, EBITDA fell 9.84% year-over-year to -$134.0 million in Q1 2026; TTM through Mar 2026 was -$398.0 million, a 8.72% increase from a year earlier, with the FY2025 full-year figure at -$386.0 million, down 16.97% from the prior year.
- EBITDA eased to -$134.0 million in Q1 2026 per RCUS's latest filing, from -$114.0 million in the prior quarter.
- Across five years, EBITDA topped out at -$8.0 million in Q2 2025 and bottomed at -$142.0 million in Q3 2025.
- The 5-year median for EBITDA is -$86.0 million (2023), against an average of -$86.5 million.
- Biggest YoY gain for EBITDA was 92.45% in 2025; the steepest drop was 662.5% in 2025.
- Year by year, EBITDA stood at -$74.0 million in 2022, then slipped by 22.97% to -$91.0 million in 2023, then dropped by 13.19% to -$103.0 million in 2024, then declined by 10.68% to -$114.0 million in 2025, then slipped by 17.54% to -$134.0 million in 2026.
- Per Business Quant, the three latest RCUS EBITDA figures stand at -$134.0 million (Q1 2026), -$114.0 million (Q4 2025), and -$142.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Arcus Biosciences | 3.57 Bn | 2.75 Bn | - | -134.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134.00 Mn |
| Dec 31, 2025 | -114.00 Mn |
| Sep 30, 2025 | -142.00 Mn |
| Jun 30, 2025 | -8.00 Mn |
| Mar 31, 2025 | -122.00 Mn |
| Dec 31, 2024 | -103.00 Mn |
| Sep 30, 2024 | -105.00 Mn |
| Jun 30, 2024 | -106.00 Mn |
| Mar 31, 2024 | -16.00 Mn |
| Dec 31, 2023 | -91.00 Mn |
| Sep 30, 2023 | -80.00 Mn |
| Jun 30, 2023 | -83.00 Mn |
| Mar 31, 2023 | -86.00 Mn |
| Dec 31, 2022 | -74.00 Mn |
| Sep 30, 2022 | -70.00 Mn |
| Jun 30, 2022 | -69.00 Mn |
| Mar 31, 2022 | -67.00 Mn |
| Dec 31, 2021 | 281.02 Mn |
| Sep 30, 2021 | -78.14 Mn |
| Jun 30, 2021 | -76.14 Mn |